Literature DB >> 10818235

Activation of PPARdelta alters lipid metabolism in db/db mice.

M D Leibowitz1, C Fiévet, N Hennuyer, J Peinado-Onsurbe, H Duez, J Bergera, C A Cullinan, C P Sparrow, J Baffic, G D Berger, C Santini, R W Marquis, R L Tolman, R G Smith, D E Moller, J Auwerx.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, which heterodimerize with the retinoid X receptor and bind to peroxisome proliferator response elements in the promoters of regulated genes. Despite the wealth of information available on the function of PPARalpha and PPARgamma, relatively little is known about the most widely expressed PPAR subtype, PPARdelta. Here we show that treatment of insulin resistant db/db mice with the PPARdelta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. The increased cholesterol was primarily associated with high density lipoprotein (HDL) particles, as shown by fast protein liquid chromatography analysis. These data were corroborated by the chemical analysis of the lipoproteins isolated by ultracentrifugation, demonstrating that treatment with L-165041 produced an increase in circulating HDL without major changes in very low or low density lipoproteins. White adipose tissue lipoprotein lipase activity was reduced following treatment with the PPARdelta ligand, but was increased by a PPARgamma agonist. These data suggest both that PPARdelta is involved in the regulation of cholesterol metabolism in db/db mice and that PPARdelta ligands could potentially have therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818235     DOI: 10.1016/s0014-5793(00)01554-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  74 in total

Review 1.  AMP-activated protein kinase and its downstream transcriptional pathways.

Authors:  Carles Cantó; Johan Auwerx
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

Review 2.  Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport.

Authors:  C Fürnsinn; T M Willson; B Brunmair
Journal:  Diabetologia       Date:  2006-11-22       Impact factor: 10.122

Review 3.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

Review 4.  Orphan nuclear receptors in drug discovery.

Authors:  Yanhong Shi
Journal:  Drug Discov Today       Date:  2007-04-26       Impact factor: 7.851

5.  Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer.

Authors:  Yaacov Barak; Debbie Liao; Weimin He; Estelita S Ong; Michael C Nelson; Jerrold M Olefsky; Richard Boland; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

Review 6.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

Review 7.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

8.  PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells.

Authors:  A M Quintela; R Jiménez; L Piqueras; M Gómez-Guzmán; J Haro; M J Zarzuelo; A Cogolludo; M J Sanz; M Toral; M Romero; F Pérez-Vizcaíno; J Duarte
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  PPAR-delta in Vascular Pathophysiology.

Authors:  Nanping Wang
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

10.  Peroxisome proliferator-activated receptor beta activation promotes myonuclear accretion in skeletal muscle of adult and aged mice.

Authors:  C Giordano; A S Rousseau; N Wagner; C Gaudel; J Murdaca; C Jehl-Piétri; B Sibille; P A Grimaldi; P Lopez
Journal:  Pflugers Arch       Date:  2009-05-05       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.